Company intelligence / Profile preview
DemeRx
Miami, Florida, United Statesdemerx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
DemeRx is conducting Phase 1 clinical trials for DMX-1001 (oral noribogaine) for Alcohol Use Disorder. The company has completed three Phase 1 pharmacokinetic studies showing DMX-1001 has a favorable safety profile with no serious adverse events reported. A new Phase 1 study is enrolling healthy volunteers with topline data from the fourth cohort anticipated in Q1 2025. The company is advancing dose selection for a Phase 2 trial for AUD treatment[4].
- Therapeutic areas
- Psychiatry
- Modalities
- Small molecules (noribogaine/DMX-1001)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Beyond the preview
Go deeper on DemeRx.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DemeRx.